MetLife estimates Q2 variable investment income at $220M-$270M

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

MetLife disclosed in an SEC filing that it estimates its variable investment income for the second quarter to be between $220 million and $270 million on a pre-tax basis.

powered bylight_fuzz_icon
44275958

*this image is generated using AI for illustrative purposes only.

MetLife estimates its variable investment income for the second quarter to be between $220 million and $270 million on a pre-tax basis, according to a regulatory filing.

The company provided the guidance in a submission to the United States Securities and Exchange Commission (SEC). Variable investment income refers to the gains or losses from MetLife's investment portfolio that are not fixed and can fluctuate based on market performance.

The disclosed range offers investors insight into the potential performance of the insurer's investment activities for the current quarter.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might current market volatility impact MetLife's ability to meet the upper end of its variable investment income guidance?

What specific asset classes are driving the expected range in variable investment income for the second quarter?

How does this guidance compare to MetLife's variable investment income performance in previous quarters?

like17
dislike

Piper Sandler raises MetLife price target to $90

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Piper Sandler analyst Paul Newsome maintains a Neutral rating on MetLife and raises the price target to $90 from $86, indicating a revised valuation outlook.

powered bylight_fuzz_icon
43864761

*this image is generated using AI for illustrative purposes only.

Piper Sandler analyst Paul Newsome has maintained a Neutral rating on MetLife (NYSE: MET) while raising the price target to $90 from $86. The revised target suggests a modest upside potential for the insurance provider's stock.

The rating update comes as the firm reassesses MetLife's valuation metrics. Despite the higher price objective, the Neutral stance indicates that the analyst expects the stock to perform in line with the broader market.

Price Target Details

The following table outlines the changes in the analyst's valuation:

Metric Previous New
Rating Neutral Neutral
Price Target $86 $90

MetLife operates as a leading provider of insurance and financial services. The stock trades on the New York Stock Exchange under the ticker symbol MET.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific valuation metrics or market conditions prompted Piper Sandler to raise the price target while maintaining a Neutral rating?

How might MetLife's upcoming earnings report influence the likelihood of an upgrade from a Neutral rating?

What are the potential risks or headwinds that could prevent MetLife from reaching the new $90 price target?

like15
dislike

More News on MetLife Inc